Inogen Inc (NASDAQ:INGN) EVP Byron Myers sold 1,846 shares of the business’s stock in a transaction dated Monday, June 18th. The stock was sold at an average price of $190.04, for a total transaction of $350,813.84. Following the sale, the executive vice president now owns 39,121 shares in the company, valued at $7,434,554.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Byron Myers also recently made the following trade(s):
Get Inogen alerts:
On Thursday, June 7th, Byron Myers sold 11,170 shares of Inogen stock. The stock was sold at an average price of $187.03, for a total transaction of $2,089,125.10.
Shares of Inogen traded down $0.86, reaching $189.14, during midday trading on Tuesday, according to MarketBeat Ratings. The company’s stock had a trading volume of 142,600 shares, compared to its average volume of 183,319. Inogen Inc has a one year low of $89.01 and a one year high of $193.14. The company has a market capitalization of $3.90 billion, a P/E ratio of 144.38, a PEG ratio of 4.62 and a beta of 1.10.
Inogen (NASDAQ:INGN) last released its earnings results on Monday, April 30th. The medical technology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.19. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The business had revenue of $79.05 million for the quarter, compared to the consensus estimate of $63.86 million. During the same period in the previous year, the firm earned $0.27 EPS. The business’s revenue for the quarter was up 50.6% on a year-over-year basis. analysts forecast that Inogen Inc will post 1.77 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in shares of Inogen in the 1st quarter worth approximately $178,000. LS Investment Advisors LLC raised its holdings in shares of Inogen by 138.6% in the 4th quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after purchasing an additional 880 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Inogen in the 1st quarter worth approximately $217,000. Suntrust Banks Inc. bought a new stake in shares of Inogen in the 4th quarter worth approximately $223,000. Finally, Jane Street Group LLC bought a new stake in shares of Inogen in the 4th quarter worth approximately $243,000. Institutional investors and hedge funds own 97.86% of the company’s stock.
A number of research firms have commented on INGN. Needham & Company LLC restated a “buy” rating on shares of Inogen in a research report on Wednesday, June 13th. Piper Jaffray Companies boosted their price target on shares of Inogen to $190.00 and gave the stock an “overweight” rating in a research report on Monday, April 30th. KeyCorp started coverage on shares of Inogen in a research report on Wednesday, June 6th. They set an “equal weight” rating on the stock. JPMorgan Chase & Co. boosted their target price on shares of Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, May 1st. Finally, Leerink Swann reiterated an “outperform” rating and issued a $170.00 target price (up from $150.00) on shares of Inogen in a report on Tuesday, May 1st. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $178.00.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.